Compugen Ltd. Stock

$1.57

3.68% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

IL0010852080

Symbol

CGEN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Compugen Ltd. Stock price

$1.57

-4.59 74.51% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.06 3.68%

ISIN

IL0010852080

Symbol

CGEN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$140.57m
Enterprise Value	$30.81m
P/E (TTM) P/E ratio	81.77
EV/Sales (TTM) EV/Sales	0.51
P/S ratio (TTM) P/S ratio	2.35
P/B ratio (TTM) P/B ratio	2.32
Revenue growth (TTM) Revenue growth	698.03%
Revenue (TTM) Revenue	$59.85m
EBIT (operating result TTM) EBIT	$10.58m
Cash position	$112.71m
EPS (TTM) EPS	$0.02
P/E forward	44.86
P/S forward	3.47
EV/Sales forward	0.76
Short interest	1.47%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Compugen Ltd. Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Compugen Ltd. forecast:

3x Buy

100%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Compugen Ltd. forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Compugen Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	60 60	698% 698% 100%
- Direct Costs	9.26 9.26	845% 845% 15%
Gross Profit	51 51	675% 675% 85%
- Selling and Administrative Expenses	10 10	0% 0% 17%
- Research and Development Expense	30 30	3% 3% 50%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	11 11	131% 131% 18%
Net Profit	1.60 1.60	105% 105% 3%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Compugen Ltd. Stock News

Neutral

PRNewsWire

●

about one month ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer Further strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitors HOLON, Israel , Nov. 27, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:...

Neutral

Seeking Alpha

●

about 2 months ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN ) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, ...

Neutral

PRNewsWire

●

about 2 months ago

Compugen Reports Third Quarter 2024 Results

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the Company Plans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance set...

More Compugen Ltd. News

Company Profile

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Head office	Israel
CEO	Anat Cohen-Dayag
Employees	68
Founded	1993
Website	www.cgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now